Rare diseases
Investigational molecules
Locations
Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease
BulgariaZenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
BulgariaA study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis
BulgariaA study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis
BulgariaEfficacy and safety of weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes not controlled by diet and exercise
PolandZenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor
BulgariaEfficacy and safety of zenagamtide versus semaglutide in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitors
BulgariaZenagamtide for Weight Loss in Adults with Obesity
BelgiumStudy of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
BulgariaA study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure
DenmarkStudy of zenagamtide for weight loss and sleep improvement in patients with obesity and obstructive sleep apnea using positive airway pressure therapy
GermanyStudy of once weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes and chronic kidney disease on basal insulin
CzechiaTell us about your condition – we search every trial in Europe and connect you with the right site.
